Courtney Rice

- Serve as a trusted advisor in rare disease, vaccines, oncology and gene therapy commercialization - Conduct due diligence for investors, manufacturers and payers on market landscape, incidence/prevalence, market size estimates, in/out licensing, tech transfer opportunities, KOL vs. practicing HCP sentiment and other forecasting inputs - Design and facilitate the development of commercialization strategy - Execute bespoke qualitative and quantitative research for stakeholders in the rare disease and gene therapy space - Inpatient reimbursement methodologies including DRG, NTAP, Fee for Service & negotiated Single Case Agreements - Seasoned market research moderator with fluency across distribution, buy and bill, practice economics, SP networks, etc

- GordonMD Global is a global biotech fund investing across the funding spectrum from venture/seed rounds to private placements to IPOs/crossovers and public equities, with a long-biased investment strategy.

- Led strategic planning function for Boston-based Rare Disease marketing practice - Worked with rare disease brand marketers to ensure the success of their well-chosen strategic imperatives and critical success factors - Ensured optimization of US and global launch strategy, positioning, payor value proposition and lifecycle management for clients' inline and pipeline brands and portfolios - Consulted on message architecture and refinement for healthcare providers, patients, caregivers, advocacy groups and payors, leveraging an internal network of Public Relations, digital, medical education and Health Economics Outcomes Research experts - Developed strategic integrated digital experiences spanning the branded and unbranded divide to facilitate growth of disease state awareness and, upon launch, to optimally position therapeutics. Development of content and social media strategy - Clients included gene therapies for monogenic diseases, ultra-rare brands, enzyme replacement therapies for rare disease, transplant and medical devices

- Due diligence for payors, PBMs, distributors, healthcare institutions & private/institutional investors - Strategic advisor for healthcare technologies aimed at streamlining reimbursement - M&A diligence incl. market sizing, qualitative KOL/SME insight, novel distribution models, patient group engagement, etc. - Lead multidisciplinary, global research teams in the mapping of previously uncharted reimbursement territory - Experience focused on biologics, specialty pharma, rare, orphan and 'ultra-orphan' diseases - Valuation of gene therapy (IV, IT, ocular and ex vivo CAR-T) - Experience with ICER and NICE evaluation processes - Advise on appropriate parameters for generating, and field resonance testing of, therapeutic value messaging including: -- Health Economics & Outcomes Research (HEOR) -- Health Care Economic Information (HCEI) -- Real World Evidence (RWE) -- Patient Reported Outcomes (PRO)

• Identified new business opportunities via networking while monitoring the current healthcare ecosystem for events that may impact current clients. • Advised drug brand managers on developing and implementing lifecycle management and brand defense strategy.

cell and gene therapy, atmp, advanced therapies, cell therapy, gene therapy, zolgensma, zynteglo, roctavian, skysona, bluebird bio, vertex, CRISPR, biomarin, libmeldy, lenmeldy, CRISPR, rare oncology, biomarkers, ALS, Alzheimer's, Friedreich Friedreich's ataxia, Parkinson's, Epidermolysis Bullosa, Sanfilippo , MPS, CLN1, CLN2, Batten Disease, EB, Pompe, CHF, hemophilia, Duchenne, muscular dystrophy, Spinal Muscular Atrophy, Fabry, lysosomal storage, GM1 gangliosidosis, frontotemporal dementia, Krabbe, ALS, SOD-1 mutation, Thalassaemia Sickle Cell, Haemophilia, Cystic Fibrosis, Tay Sachs disease, Fragile X syndrome, Thalassaemia, Prader-Willi, Turner Syndrome, adrenoleukodystrophy, Charcot-Marie-Tooth disease, FOP, Rett Syndrome, Batten Disease, SMA, AAV, AAV9, vector, promoter, chimeric, self-complementary, gene editing, repeat dose, lymphoblastic leukemia, ALL, AAV8, retinal, genetic root cause, diagnostics, newborn screening, neuromuscular, central nervous system, CNS, manufacturing, T cell therapy, hematological malignancies, CAR-T, Editas, gene therapy launch, commercialization, commercial, genome editing, allogeneic, liver, Generation, retina, capsid-free, monogenic, ICM, adeno-associated, autologous, mRNA, payload, brand manager, Genetic Diagnostics, Market Access Consulting, Government Pricing & Reporting, Trade & Distribution, Payer Landscape assessment, Product coding pathway towards reimbursement, Value Strategy and Value Proposition development. Payer / Pricing Strategy and Executive Payer Engagement. RWE, RWD, genomics, patient registries, market access, managed care, payers, Real World Evidence, Real World Data, Molecular Diagnostics Utilization Management, Diagnostics Management, Genomics, Medical Management, Value and Access, Pricing, HEOR, RWE, RWD, US Market Access Strategy, Payer, Physician and Specialty Pharmacy Contracting, Trade & Distribution, Gross-to-Net and Revenue Forecasting